Novartis positive 52-week PREVENT data confirm Cosentyx efficacy in addressing entire axSpA spectrum.

Novartis, announced additional positive data from the PREVENT trial, evaluating the efficacy and safety of Cosentyx (secukinumab) in patients with non-radiographic axial spondyloarthritis (nr-axSpA). The ongoing Phase III trial met its primary endpoint of ASAS40 at Week 52, showing a significant and clinically meaningful reduction in disease activity for patients treated with Cosentyx versus placebo.

The trial demonstrated a sustained response and a safety profile consistent with previous clinical trials. No new safety signals were detected. Positive 16-week PREVENT data were announced mid-September and submitted to EMA for approval in nr-axSpA. These data add to the five-years of clinical data supporting the long-term efficacy and safety of Cosentyx across ankylosing spondylitis, psoriatic arthritis and psoriasis.Detailed data is planned to be presented at a future scientific congress.